IPO
Innovative approach for hard-to-treat cancers being developed at the Cancer Research UK Beatson Institute
CELLINK publishes the quarterly report for the period 1st of June 2019 – 31st of August 2019 and for the full year of operations 2018-2019.
BioArctic and Eisai presented new data regarding BAN2401 at the Alzheimer’s Association International Conference® (AAIC®) in July that confirmed BAN2401’s unique characteristics and was consistent with previously presented results
Adocia, a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases with innovative formulations of proteins and peptides, announced third quarter revenue and net cash position as of September 30, 2019.
MorphoSys AG will publish its first nine months’ 2019 results on October 29, 2019 at 10:00pm CET
Promore Pharma AB held Extraordinary Shareholder’s Meeting on Tuesday, 22 October 2019.
HBM Healthcare Investments, Vivo Capital, BlackRock, Omega Funds, Pivotal BioVentures, and Goldman Sachs join existing investors Frazier Healthcare Partners, Bain Capital Life Sciences, OrbiMed and RA Capital Management
Companies have raised over 6x more investment thanks to grant funding
Corteva Agriscience announced a $500,000 commitment to create the Corteva Agriscience Climate Positive Challenge to catalyze a movement toward climate-positive agriculture.
Pharnext SA, a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big genomics data and artificial intelligence, announced its financial results for first-half 2019.
PRESS RELEASES